Regorafenib is an orally-administered inhibitor of multiple kinases. It is used to treat metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors, Tyrosine Kinase Inhibitors and VEGF inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Stivarga and Regorafenibum. Its PubChem CID is 11167602.
Regorafenib
| CAS No | 755037-03-7 |
|---|---|
| Molecular Formula | C21H15ClF4N4O3 |
| Molecular Weight | 482.8 g/mol |
| Synonyms | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used to treat metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma.
The listed CAS number is 755037-03-7.
The listed molecular formula is C21H15ClF4N4O3.
The listed molecular weight is 482.8 g/mol.
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide.
The source lists Stivarga and Regorafenibum.